Novel Anticoagulants for Non-valvular Atrial Fibrillation

Heart Lung and Circulation

Volumn 21, Issue 8, 2012, Pages 463-467

  Xu, Bo ^a   Whitbourn, Robert ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Anticoagulation; Apixaban; Atrial fibrillation; Dabigatran; Rivaroxaban; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN ETEXILATE; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; NONVALVULAR HEART ATRIUM FIBRILLATION; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM; CEREBROVASCULAR ACCIDENT; FEMALE; MALE; METHODOLOGY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG MONITORING; EMBOLISM; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84863814810     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2012.04.002     Document Type: Review

References (19)

1. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly. Arch Intern Med 1987, 147(9):1561-1564.
2. van Walraven C., Hart R.G., Singer D.E., Laupacis A., Connolly S., Petersen P., et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002, 288(19):2441-2448.
3. Go A.S., Hylek E.M., Borowsky L.H., Phillips K.A., Selby J.V., Singer D.E. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999, 131(12):927-934.
4. Cabral K.P., Ansell J., Hylek E.M. Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification. J Thromb Haemost 2011, 9:441-449.
5. Eriksson B.I., Borris L.C., Friedman R.J., Haas S., Huisman M.V., Kakkar A.K., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358:2765-2775.
6. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365(10):883-891.
7. Granger C.B., Alexander J.H., McMurray J.J., Lopes R.D., Hylek E.M., Hanna M., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365(11):981-992.
8. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
9. Rang H.P., Dale M.M., Ritter J.M. Pharmacology 2001, Churchill Livingstone, Harcourt Publishers Limited, Edinburgh, p. 315-8. 4th ed.
10. Eikelboom J.W., Wallentin L., Connolly S.J., Ezekowitz M., Healey J.S., Oldgren J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011, 123:2363-2372.
11. Pharmaceutical Benefits Scheme. Dabigatran. [accessed 18.10.2011]. http://www.pbs.gov.au/pbs/search%3Fterm=dabigatran.
12. Pharmaceutical Benefits Scheme. Rivaroxaban. [accessed 18.10.2011]. http://www.pbs.gov.au/pbs/search%3Fterm=rivaroxaban.
13. ® (dabigatran etexilate) 2011.
14. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., Meijers J.C., Buller H.R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124(14):1573-1579.
15. Godier A., Miclot A., Le Bonniec B., Durand M., Fischer A.M., Emmerich J., et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012, 116(1):94-102.
16. van Ryn J., Litzenburger T., Waterman A., Canada K., Hauel N., Sarko C., et al. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol 2011, 57:E1130.
17. Lu G., DeGuzman F.R., Lakhotia S., Hollenbach S.J., Phillips D.R., Sinha U. Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors. Blood 2008, 112:362. [abstract 983].
18. Camm A.J., Kirchhof P., Lip G.Y., Schotten U., Savelieva I., Ernst S., et al. Guidelines for the management of atrial fibrillation. Eur Heart J 2010, 31:2369-2429.
19. Wann L.S., Curtis A.B., January C.T., Ellenbogen K.A., Lowe J.E., Estes N.A., et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 123:104-123.